AGIO Historical PE Ratio Notes

— Agios Pharmaceuticals (AGIO) is a biopharmaceutical company focused on developing medicines in the field of cellular metabolism, with a particular emphasis on rare genetic diseases and disorders like pyruvate kinase (PK) deficiency and thalassemia. AGIO's transition from oncology to rare diseases, especially after divesting its cancer portfolio, means its earnings profile has historically been volatile, with high research & development spending and minimal or negative net income as products have only recently reached the commercialization stage. This business model has a direct impact on AGIO’s historical PE ratio: in years with negative earnings (losses), the PE ratio will be undefined or not meaningful, and early positive PE ratios may be extremely high due to small or fluctuating profits. Investors analyzing historical PE ratios for AGIO will observe periods where the ratio jumps erratically or appears as — (not applicable), reflecting the shift from a research-driven biotech to one with growing product revenues. Understanding AGIO’s business milestones, pipeline progress, and industry context is crucial when interpreting these financials, as the traditional use of PE ratios is less informative for high-growth biotechs unless and until sustainable earnings are established.

On this page we presented the AGIO Historical PE Ratio information for Agios Pharmaceuticals' stock. The average AGIO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 91.2. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AGIO historical PE based on this TTM earnings result method is 22.1. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AGIO historical PE result, against the recent PE: when this page was posted on 5/4/2026, the most recent closing price for AGIO had been 27.56, and the most recent quarterly earnings result, annualized, was 0.4. Meanwhile, the most recent TTM earnings summed to 1.68. From these numbers, we calculate the recent AGIO PE on 5/4/2026 based on annualized quarterly EPS was 68.9. Based on AGIO's history, that recent PE is low relative to the historical average, with the recent PE 24.5% lower than the historical average PE across our data set for Agios Pharmaceuticals. Looking at the recent AGIO PE on 5/4/2026 based on TTM EPS, we calculate the ratio at 16.4. Based on AGIO's history, that recent PE is low relative to the historical average, with the recent PE 25.8% lower than the average PE across our Agios Pharmaceuticals data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on AGIO or any other given stock, valuation analysis for AGIO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Agios Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AGIO. Thanks for visiting, and the next time you need to research AGIO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.